NewcelX shares jump 13.88% premarket after appointing Swiss pharma leader Dr. Julien Boisdron to Scientific Advisory Board to advance diabetes therapies.

NewcelX surged 13.88% in premarket trading following the announcement of Dr. Julien Boisdron’s appointment to its Scientific Advisory Board. Dr. Boisdron, a seasoned diabetes expert with two decades of leadership in Swiss big pharma, will guide the development of IsletRx, NewcelX’s stem-cell-derived islet cell therapy for Type 1 Diabetes. The hiring of a high-profile industry leader in the company’s core therapeutic area signals enhanced credibility and strategic momentum, particularly for advancing its lead program toward clinical trials. The news aligns with the stock’s sharp premarket rise, reflecting investor optimism about strengthened expertise in diabetes innovation and potential near-term clinical progress.